We believe in our ability to
Change the future
Novel Therapy Development for Alzheimer's Disease
Northwood Conlsultants have focused their development programme on novel lipids exhibiting anti-inflammatory properties
Many Years of Knowledge and Experience
Lipid research has been the focus of our work for many years resulting in a number of patents and publications.
Focused purely on changing other people's lifes
AD can take up to 20 years from disease initiation to the development of symptoms.
Scientists determined to develop the cure
Northwood Consultants platform technology is based on naturally occurring poly-unsaturated lipids. It is known, for example, that diet is a factor in Alzheimer’s disease (AD). In addition, from epidemiological studies, it has been shown that some populations have a lower incidence of AD than others. Some data suggest that a diet rich in lipids containing poly-unsaturated fatty acids (PUFAs) confer some protection in this dementia.
AD was first described by Alois Alzheimer in 1906 but since it was described until the present day no treatment has been developed that prevents this disease.
Northwood Consultants is seeking long-term support for our research programme in the form of strategic partners who can contribute to and progress the NWC technology from lab to clinic.
Scientists determined to develop the cure
Northwood Consultants platform technology is based on naturally occurring poly-unsaturated lipids. It is known, for example, that diet is a factor in Alzheimer’s disease (AD). In addition, from epidemiological studies, it has been shown that some populations have a lower incidence of AD than others. Some data suggest that a diet rich in lipids containing poly-unsaturated fatty acids (PUFAs) confer some protection in this dementia.
AD was first described by Alois Alzheimer in 1906 but since it was described until the present day no treatment has been developed that prevents this disease.
Northwood Consultants is seeking long-term support for our research programme in the form of strategic partners who can contribute to and progress the NWC technology from lab to clinic.
Novel Therapy Development
Northwood Consultants have focused their development programme on novel lipids exhibiting anti-inflammatory properties. Neuroinflammation is characterised by activated brain cells (microglia) secreting inflammatory mediators including tumour necrosis-alpha (TNFα) and interleukin-6 (IL-6) among others. Inhibiting inflammatory cytokines is a fast-growing area of AD research.
Many Years of Knowledge and Experience
Lipid research and development has been the focus of our work for many years resulting in a number of patents and publications. As an example, the Coupland lab in the UK developed the first successful lipid intervention for a rare genetic disease adrenoleukodystrophy (ALD). ALD is characterized by the accumulation of toxic- very long chain fatty acids in the brain. The lipid developed by us became known as Lorenzo’s oil and was featured in the Hollywood movie of the same name.
Focused purely on changing other people's lifes
AD can take up to 20 years from disease initiation to the development of symptoms. The disease is relentless in its progression from mild cognitive impairment to a condition requiring constant supervision or hospitalization. AD not only affects the diseased individual but also close family and friends who carry the emotional burden. The global spend on healthcare for people with dementia is estimated at more than $590 billion.
Novel Therapy Development
Northwood Consultants have focused their development programme on novel lipids exhibiting anti-inflammatory properties. Neuroinflammation is characterised by activated brain cells (microglia) secreting inflammatory mediators including tumour necrosis-alpha (TNFα) and interleukin-6 (IL-6) among others. Inhibiting inflammatory cytokines is a fast-growing area of AD research.
Many Years of Knowledge and Experience
Lipid research and development has been the focus of our work for many years resulting in a number of patents and publications. As an example, the Coupland lab in the UK developed the first successful lipid intervention for a rare genetic disease adrenoleukodystrophy (ALD). ALD is characterized by the accumulation of toxic- very long chain fatty acids in the brain. The lipid developed by us became known as Lorenzo’s oil and was featured in the Hollywood movie of the same name.
Focused purely on changing other people's lifes
AD can take up to 20 years from disease initiation to the development of symptoms. The disease is relentless in its progression from mild cognitive impairment to a condition requiring constant supervision or hospitalization. AD not only affects the diseased individual but also close family and friends who carry the emotional burden. The global spend on healthcare for people with dementia is estimated at more than $590 billion.